Medicines for Europe has set out a string of policy recommendations highlighting key areas for reform, as part of a “structured dialog” initiated with pharmaceutical industry stakeholders by the European Commission.
Launched earlier this year, the structured dialog was welcomed by Medicines for Europe as an opportunity to bolster the environment for local manufacturing and address weaknesses in the stability and security of the supply chain